Publications
View AllUse of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial
Purpose The European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada trial on temozolomide (TMZ) and radiotherapy (RT) in glioblastoma ...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- DE
- Publications
- 4
- Citations
- 12,272
External Links
Identifiers
- ROR
- https://ror.org/00pjgxh97